FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:1340-1345 May 10, 1990 Number 19 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We conducted a Phase I open-label trial of 2',3'-dideoxyinosine (ddI) for the treatment of the acquired immunodeficiency syndrome (AIDS) and severe AIDS-related complex. A single daily dose of ddI was administered orally to 34 patients (17 with AIDS and 17 with AIDS-related complex) for a median of 12 weeks (range, 2 to 56). We studied six dose levels from 1.6 to 30.4 mg per kilogram of body weight per day. Of the 17 patients previously treated with zidovudine, 13 had had hematologic side effects. The maximal tolerated dose of oral ddI was estimated to be 20.4 mg per kilogram per day. Pancreatitis and peripheral neuropathy were the major dose-limiting toxic effects. Other toxic effects included elevations in hepatic transaminase levels, abnormalities in cardiac conduction, rash, and asymptomatic elevations in serum urate levels and the creatine kinase fraction from skeletal muscle. Treatment with ddI was associated with an increase in the mean number of CD4 lymphocytes from 125 per cubic millimeter at base line to 182 per cubic millimeter after 10 weeks (P = 0.005). There were also increases after 12 weeks in the mean total lymphocyte count (from 0.8 to 1.2 x 10(9) per liter) and the mean hemoglobin level (from 12.9 to 14.1 g per deciliter) (both P less than 0.01). The amount of human immunodeficiency virus p24 antigen decreased by more than 50 percent in 14 of 19 patients with detectable antigen. No differences in response were observed between patients previously treated with zidovudine and those never treated with the drug. We conclude that ddI has antiretroviral activity in patients with AIDS or AIDS-related complex and that the toxicity of ddI differs from that of zidovudine. However, controlled trials are necessary to evaluate the efficacy of ddI.

Source Information

Department of Medicine, Boston City Hospital, MA 02118.

This article has been cited by other articles:

• Halvas, E. K., Svarovskaia, E. S., Freed, E. O., Pathak, V. K. (2000). Wild-Type and YMDD Mutant Murine Leukemia Virus Reverse Transcriptases Are Resistant to 2',3'-Dideoxy-3'-Thiacytidine. J. Virol. 74: 6669-6674 [Abstract] [Full Text]  
• McArthur, J. C., Yiannoutsos, C., Simpson, D. M., Adornato, B. T., Singer, E. J., Hollander, H., Marra, C., Rubin, M., Cohen, B. A., Tucker, T., Navia, B. A., Schifitto, G., Katzenstein, D., Rask, C., Zaborski, L., Smith, M. E., Shriver, S., Millar, L., Clifford, D. B. (2000). A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology 54: 1080-1088 [Abstract] [Full Text]  
• Berger, A. R., Schaumburg, H. H., Gourevitch, M. N., Freeman, K., Herskovitz, S., Arezzo, J. C. (1999). Prevalence of peripheral neuropathy in injection drug users. Neurology 53: 592-592 [Abstract] [Full Text]  
• Chang, M., Sood, V. K., Kloosterman, D. A., Hauer, M. J., Fagerness, P. E., Sanders, P. E., Vrbanac, J. J. (1997). Identification of the Metabolites of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine in Monkeys. Drug Metab. Dispos. 25: 814-827 [Abstract] [Full Text]  
• Chang, M., Sood, V. K., Wilson, G. J., Kloosterman, D. A., Sanders, P. E., Hauer, M. J., Zhang, W., Branstetter, D. G. (1997). Metabolism of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine In Mice. Drug Metab. Dispos. 25: 828-839 [Abstract] [Full Text]  
• Cui, L., Locatelli, L., Xie, M.-Y., Sommadossi, J.-P. (1997). Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells. J. Pharmacol. Exp. Ther. 280: 1228-1234 [Abstract] [Full Text]  
• Chang, M., Sood, V. K., Wilson, G. J., Kloosterman, D. A., Sanders, P. E., Hauer, M. J., Fagerness, P. E. (1997). Metabolism of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Delavirdine in Rats. Drug Metab. Dispos. 25: 228-242 [Abstract] [Full Text]  
• Abrams, D. I., Goldman, A. I., Launer, C., Korvick, J. A., Neaton, J. D., Crane, L. R., Grodesky, M., Wakefield, S., Muth, K., Kornegay, S., Cohn, D. L., Harris, A., Luskin-Hawk, R., Markowitz, N., Sampson, J. H., Thompson, M., Deyton, L., The Terry Beirn Community Programs for Clinical Re, (1994). A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection. NEJM 330: 657-662 [Abstract] [Full Text]  
• Saag, M. S., Emini, E. A., Laskin, O. L., Douglas, J., Lapidus, W. I., Schleif, W. A., Whitley, R. J., Hildebrand, C., Byrnes, V. W., Kappes, J. C., Anderson, K. W., Massari, F. E., Shaw, G. M., The 661 Working Group L-697, (1993). A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. NEJM 329: 1065-1072 [Abstract] [Full Text]  
• Hirsch, M. S., D'Aquila, R. T. (1993). Therapy for Human Immunodeficiency Virus Infection. NEJM 328: 1686-1695 [Full Text]  
• Johnston, M., Hoth, D. (1993). Present status and future prospects for HIV therapies. Science 260: 1286-1293 [Abstract]  
• Mitsuya, H, Yarchoan, R, Broder, S (1990). Molecular targets for AIDS therapy. Science 249: 1533-1544 [Abstract]  
• (1990). DDI FOR AIDS/ARC: PRELIMINARY RESULTS ARE ENCOURAGING. JWatch General 1990: 4-4 [Full Text]